Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458695 | 0.88 | ADRA1B (0.46) | ADRA1AADRA1DADRA1BTSHR | |
| SCHEMBL14458720 | 0.80 | ADRA1B (0.49) | ADRA1AADRA1DADRA1BL3MBTL1 | |
| SCHEMBL14458711 | 0.79 | L3MBTL1 (0.39) | ADRA1BL3MBTL1TSHR | |
| SCHEMBL6253602 | 0.78 | ADRA1B (0.47) | ADRA1AADRA1DADRA1BL3MBTL1 | |
| SCHEMBL14458725 | 0.78 | ADRA1B (0.47) | ADRA1AADRA1DADRA1BL3MBTL1 | |
| SCHEMBL5561359 | 0.78 | HTR1A (0.48) | ADRA1AADRA1DADRA1BL3MBTL1 | |
| SCHEMBL14458710 | 0.74 | L3MBTL1 (0.38) | ADRA1AADRA1DL3MBTL1TSHR | |
| SCHEMBL6111104 | 0.74 | L3MBTL1 (0.51) | ADRA1AADRA1DL3MBTL1 | |
| SCHEMBL6253311 | 0.74 | L3MBTL1 (0.51) | ADRA1AADRA1DADRA1BL3MBTL1 | |
| SCHEMBL6252228 | 0.73 | L3MBTL1 (0.54) | ADRA1AADRA1DL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | ADRA1A 126/4885ADRA1D 73/4885ADRA1B 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.